Overview

• Bayer lifted its 2025 revenue guidance to €46 billion–€48 billion and its adjusted EBITDA forecast to €9.7 billion–€10.2 billion.
• The company increased special charges for US litigation to between €2.5 billion and €3.5 billion, up from the prior estimate of €1.5 billion.
• In the second quarter, revenue declined about 4 percent to €10.7 billion while adjusted EBITDA held steady at €2.1 billion, surpassing analysts’ midpoint estimates.
• A settlement with a plaintiffs’ law firm reduced Bayer’s outstanding glyphosate lawsuits to roughly 61,000 cases.
• The US Supreme Court will consider federal preemption of state glyphosate warnings during its 2025/26 term, with a decision expected by June 2026.